Latest stories on AMRN
Amarin Corp PLC Reports Q3 2026 Earnings: EPS of $0.02, Revenue of $39.6 Million Despite Competitive Pressures
GuruFocus42 · neutralearnings
AMARIN CORP PLC\UK (AMRN) files 8-K
SEC 8-K50 · neutralgeneral
Amarin’s Q3 revenue drops amid U.S. pricing pressure
Seeking Alpha42 · neutralearnings
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
StockTitan64 · neutralearnings
Amarin (AMRN) Set to Report Q3 Earnings Amid Price-to-Sales Valuation Scrutiny
GuruFocus50 · neutralearnings
Amarin Q3 Earnings Preview
Seeking Alpha50 · neutralearnings
Amarin announces EPA for Metastasis Trial 2 did not meet primary endpoint
The Fly22 · bearishearnings
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
GlobeNewswire42 · neutralproduct/pr
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
StockTitan53 · neutralproduct/pr
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
GlobeNewswire50 · neutralgeneral
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - qz.com
Quartz56 · neutralgeneral
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Business Insider63 · neutralproduct/pr
Amarin analysis links Vascepa adherence to greater, longer-lasting heart benefits
Seeking Alpha67 · bullishproduct/pr
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
Business Insider55 · neutralproduct/pr
Amarin reinstated with an Underweight at JPMorgan
The Fly34 · bearishanalyst
Amarin (AMRN) Q2 2026 Earnings Call Transcript
The Motley Fool59 · neutralearnings
Amarin expects positive full-year 2026 cash flow as VASCEPA market share reaches 48% and Europe demand rises 69%
Seeking Alpha67 · bullishproduct/pr
Amarin Corporation plc (AMRN) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
AMARIN CORP PLC\UK (AMRN) files 8-K
SEC 8-K50 · neutralgeneral
Amarin Reports Second-Quarter Results as Partnered International Strategy Gains Momentum
InvestorsHub63 · neutralearnings
Amarin Reports Second-Quarter Results as Partnered International Strategy Gains Momentum
Yahoo Top63 · neutralearnings
Amarin Q2 Earnings Call Highlights
Yahoo Top56 · neutralearnings
Amarin misses Q2 topline estimates
Seeking Alpha34 · bearishearnings